Zwierzina H, Schöllenberger S, Herold M, Schmalzl F, Besemer J
Medizinische Universitätsklinik Innsbruck, Austria.
Leuk Res. 1992 Dec;16(12):1181-6. doi: 10.1016/0145-2126(92)90116-o.
The majority of patients suffering from myelodysplastic syndromes (MDS) die of complications due to cytopenia. Clinical trials have demonstrated that in an essential number of MDS patients cytopenia can be ameliorated by exogenously supplied growth factors. We investigated endogenous serum levels of GM-CSF and IL-3 in 15 healthy individuals and 34 patients suffering from MDS. No circulating growth factors were detected in the serum of healthy controls, nor was IL-3 measurable in MDS patients. GM-CSF serum levels, however, were elevated in a significant number of patients (26.5%). Levels did not correlate with FAB classification, leukocyte count or chromosomal abnormalities. No significant differences in GM-CSF or IL-3 receptor expression were detected between healthy individuals and MDS patients. One patient with increased endogenous GM-CSF serum level and normal surface receptor expression responded to exogenously applied GM-CSF. In the light of these results, a functional alteration of growth factor receptors or disturbances of signal transduction pathways must be discussed for MDS.
大多数骨髓增生异常综合征（MDS）患者死于血细胞减少引起的并发症。临床试验表明，相当数量的MDS患者的血细胞减少可通过外源性提供生长因子得到改善。我们调查了15名健康个体和34名MDS患者的内源性血清GM-CSF和IL-3水平。在健康对照者的血清中未检测到循环生长因子，MDS患者中也检测不到IL-3。然而，相当数量的患者（26.5%）GM-CSF血清水平升高。其水平与FAB分型、白细胞计数或染色体异常无关。在健康个体和MDS患者之间未检测到GM-CSF或IL-3受体表达的显著差异。一名内源性GM-CSF血清水平升高且表面受体表达正常的患者对外源性应用的GM-CSF有反应。鉴于这些结果，对于MDS必须讨论生长因子受体的功能改变或信号转导途径的紊乱。
